Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to HumiraBELLEVUE, Wash., June 29, 2026 (GLOBE ...
Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...
Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...
The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep ...
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in more than five ...
These healthcare stocks may be the building blocks of a winning portfolio.
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a ...
Arizona employers face a reality: health care costs continue to rise driven primarily by pharmaceutical innovation that is ...
Earlier this week, AbbVie reported European Commission approvals extending Skyrizi to children with moderate to severe plaque ...
Definium's Phase 3 LSD trial for depression beats with an 8.1-pt MADRS improvement, sending shares up 30%+ premarket. AbbVie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results